Filing Flows › Boston Scientific (BSX) › Q3 2026 › vs Q2 2026
Boston Scientific (BSX) Q3 2026 vs Q2 2026 (quarter over quarter)
Boston Scientific's revenue fell $304M (-6%) from $5.4B in Q2 2026 to $5.1B in Q3 2026. The biggest changes: Electrophysiology −$100M (-11%); Interventional Cardiology & Vascular Therapies −$60.0M (-5%); Endoscopy −$52.0M (-7%). Gross margin 66.7% against 70.7% (-4.0 pts).
Boston Scientific, Q3 2026: revenue $5.1B (+1% year over year), operating margin 16.1%, net earnings $580M, operating cash flow $1.0B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 66.7% | 70.7% | -4.0 pts |
| Operating margin | 16.1% | 21.6% | -5.5 pts |
| Net margin | 11.3% | 16.6% | -5.3 pts |
| Free cash flow margin | 16.9% | 23.5% | -6.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Interventional Cardiology & Vascular Therapies | $1.3B | $1.3B | −$60.0M | -5% |
| Electrophysiology | $816M | $916M | −$100M | -11% |
| Endoscopy | $741M | $793M | −$52.0M | -7% |
| Urology | $661M | $684M | −$23.0M | -3% |
| Cardiac Rhythm Management | $568M | $585M | −$17.0M | -3% |
| Watchman | $482M | $507M | −$25.0M | -5% |
| Neuromodulation | $331M | $341M | −$10.0M | -3% |
| Interventional Oncology & Embolization | $267M | $283M | −$16.0M | -6% |
| Revenue | $5.1B | $5.4B | −$304M | -6% |
| Gross profit | $3.4B | $3.8B | −$420M | -11% |
| Cost of revenue | $1.7B | $1.6B | $116M | +7% |
| Operating profit | $828M | $1.2B | −$350M | -30% |
| Operating expenses | $2.6B | $2.7B | −$70.0M | -3% |
| Pre-tax earnings | $733M | $1.1B | −$327M | -31% |
| Other expense, net | $95.0M | $118M | −$23.0M | -19% |
| Research & development | $520M | $554M | −$34.0M | -6% |
| SG&A | $1.7B | $1.8B | −$120M | -7% |
| Other operating costs | $397M | $313M | $84.0M | +27% |
| Net earnings | $580M | $905M | −$325M | -36% |
| Income tax | $153M | $155M | −$2.0M | -1% |
| Depreciation & amortization | $361M | $355M | $6.0M | +2% |
| Share-based compensation | $72.0M | $87.0M | −$15.0M | -17% |
| Working capital & other | $35.0M | $127M | −$92.0M | -72% |
| Operating cash flow | $1.0B | $1.5B | −$426M | -29% |
| Free cash flow (OCF − capex) | $868M | $1.3B | −$411M | -32% |
| Capital expenditures | $180M | $195M | −$15.0M | -8% |
Questions
How much did Boston Scientific's revenue grow quarter over quarter in Q3 2026?
Boston Scientific's revenue fell $304M (-6%) from $5.4B in Q2 2026 to $5.1B in Q3 2026.
What drove Boston Scientific's revenue change in Q3 2026?
Electrophysiology −$100M (-11%); Interventional Cardiology & Vascular Therapies −$60.0M (-5%); Endoscopy −$52.0M (-7%).